Nanotechnology in ophthalmic drug delivery

Patenting Nanomedicines: Legal Aspects, Intellectual Property and Grant Opportunities

Volumn 9783642292651, Issue , 2012, Pages 277-303

  Al Kinani, Ali A ^a   Calabrese, Gianpiero ^a   Vangala, Anil ^a   Naughton, Declan ^a   Alany, Raid G ^a  

^a KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Delivery systems; Nanotechnology patents; Ophthalmic drug delivery

Indexed keywords

EID: 84886616136     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-29265-1_9     Document Type: Chapter

References (111)

1. Abdelkader H, Patel DV, McGhee CN, Alany RG (2011a) New therapeutic approaches in the treatment of diabetic keratopathy: a review. Clin Experiment Ophthalmol 39(3): 259-270
2. Abdelkader H, Ismail S, Kamal A, Alany RG (2011b) Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J Pharm Sci 100(5): 1833-1846
3. Abdelkader H, Wu Z, Al-Kassas R, Brown JE, Alany RG (2011c) Preformulation characteristics of the opioid growth factor antagonist-naltrexone hydrochloride: stability and lipophilicity studies. J Drug Deliv Sci Technol 21(2): 157-163
4. Abdelkader H, Patel D, Mcghee C, Alany RG (2011d) New therapeutic approaches in the treatment of neurotrophic keratopathy. Clin Experiment Ophthalmol 39: 259-270
5. Ahmed I, Patton TF (1985) Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 26(4): 584-587
6. Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM (2006) Water in oil microemulsions for ocular drug delivery: evaluation of ocular irritation and precorneal retention. J Control Release 111: 145-152
7. Bell SJD, He Q, Chu T, Potter DE (2004) Intraocular delivery compositions and methods. World Patent 2004/050065
8. Bhadra D, Bhadra S, Jain S, Jain NK (2003) A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 257(1-2): 111-124
9. Bill A, Sperber G, Ujiie K (1983) Physiology of the choroidal vascular bed. Int Ophthalmol 6(2): 101-107
10. Budai L, Hajdú M, Budai M, Gróf P, Béni S, Noszál B et al (2007) Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. Int J Pharm 343(1-2): 34-40
11. Cavalli R, Morel S, Gasco MR, Chetoni P, Saettone MF (1995) Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int J Pharm 117(2): 243-246
12. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF (2002) Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238(1-2): 241-245
13. Chan J, Craig JP, Elmaghraby GMM, Alany RG (2007) Phase transition water - in - oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm 328(1): 65-71
14. Chan J, Craig JP, Elmaghraby GMM, Alany RG (2008) Effect of water - in - oil microemulsions and lamellar liquid crystalline systems on the precorneal tear film of albino New Zealand rabbits. Clin Ophthalmol 2(1): 1-9
15. Chang JN (2010) Recent advances in ophthalmic drug delivery. In: Kulkarni VS (ed) Handbook of non-invasive drug delivery systems, 1st edn. Elsevier, Burlington
16. Chen H, Khemtong C, Yang X, Chang X, Gao J (2011) Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 16(7-8): 354-360
17. Constantinides PP, Chaubal MV, Shorr R (2008) Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Deliv Rev 60(6): 757-767
18. Cunha-Vaz J (1979) The blood-ocular barriers. Surv Ophthalmol 23(5): 279-296
19. Diebold Y, Calonge M (2010) Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29(6): 596-609
20. Ding S (1998) Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1(8): 328-335
21. Durairaj C, Kadam RS, Chandler JW, Hutcherson SL, Kompella UB (2010) Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci 51(11): 5804-5816
22. Duvvuri S, Majumdar S, Mitra AK (2003) Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 3(1): 45-56
23. El-Gazayerly ON, Hikal AH (1997) Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int J Pharm 158(2): 121-127
24. European Medical Research Councils (EMRC) (2005) Nanomedicine, An ESF - Forward Look report
25. Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R (1999) Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention. Int J Pharm 180(2): 185-193
26. Franks A (1987) Nanotechnology. J Phys E Sci Instrum 20(12): 1442
27. Freedman KA, Klein JW, Crosson CE (1993) Beta-cyclodextrins enhance bioavailability of pilocarpine. Curr Eye Res 12(7): 641-647
28. Galan Valdivia FJ, Coll Dachs A, Carreras Perdiguer N (2003) Nanoemulsion of the oil in water type, useful as an ophthalmic vehicle and process for the preparation thereof. European Patent 0696452 B1
29. Gasco MR (2005) Nanoparticles as vehicles for nucleic acids, process for their preparation and use. World Patent 2005/120469
30. Gasco MR, Zara GP, Saettone MF (2005) Pharmaceutical compositions suitable for the treatment of ophthalmic diseases. World Patent 2004/039351
31. Grinstaff MW, Carnahan MA (2006) Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses. World Patent 2006/031358
32. Gurny R (1981) Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma. Pharm Acta Helv 56(4-5): 130-132
33. Gurny R, Boye T, Ibrahim H (1985) Ocular therapy with nanoparticulate systems for controlled drug delivery. J Control Release 2: 353-361
34. Guyton AC, Hall JE (2006) The Eye: II. Receptor and neural function of the retina. Textbook of medical physiology, 11th edn. Elsevier, New York
35. Hamalainen KM, Kananen K, Auriola S, Kontturi K, Urtti A (1997) Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 38(3): 627-634
36. Hamidi M, Azadi A, Rafiei P (2008) Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 60(15): 1638-1649
37. Hara H, Takeuchi H (2010) Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye. European Patent 2255788 A1
38. Harush-Frenkel O, Altschuler Y, Benita S (2008) Nanoparticle-cell interactions: drug delivery implications. Crit Rev Ther Drug Carrier Syst 25(6): 485-544
39. Hofland H, Bongianni J, Wheeler T (2004) Ophthalmic liposome compositions and uses thereof. United States Patent 2004/0224010 A1
40. Hornof M, Toropainen E, Urtti A (2005) Cell culture models of the ocular barriers. Eur J Pharm Biopharm 60(2): 207-225
41. Huang AJ, Tseng SC, Kenyon KR (1989) Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci 30(4): 684-689
42. Ihre HR, Padilla De Jesus OL, Szoka FC Jr, Frechet JM (2002) Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug Chem 13(3): 443-452
43. Janoria KG, Gunda S, Boddu SHS, Mitra AK (2007) Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 4(4): 371-388
44. Jumbe NL, Miller MH (2003) Ocular drug transfer following systemic drug administration. In: Mitra AK (ed) Ophthalmic drug delivery systems, 2nd edn. Marcel Dekker, New York
45. Kaur IP, Garg A, Singla AK, Aggarwal D (2004) Vesicular systems in ocular drug delivery: an overview. Int J Pharm 269(1): 1-14
46. Kayser O, Lemke A, Hernandez-Trejo N (2005) The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 6(1): 3-5
47. Ketelson HA, Meadows DL (2003a) Synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs. World Patent 2003/059194
48. Ketelson HA, Meadows DL (2003b) Nanoparticles as carriers for biocides in ophthalmic compositions. World Patent 2003/059193
49. Klein HZ, Lugo M, Shields MB, Leon J, Duzman E (1985) A dose-response study of piloplex for duration of action. Am J Ophthalmol 99(1): 23-26
50. Krauland AH, Leitner VM, Bernkop-Schnurch A (2003) Improvement in the in situ gelling properties of deacetylated gellan gum by the immobilization of thiol groups. J Pharm Sci 92: 1234-1241
51. Kyyronen K, Urtti A (1990) Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine. Invest Ophthalmol Vis Sci 31(9): 1827-1833
52. Lang JC (1995) Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev 16(1): 39-43
53. Laroche L, Arrata M, Brasseur G, Lagoutte F, Le Mer Y, Lumbroso P et al (1991) Treatment of dry eye syndrome with lachrymal gel: a randomized multicenter study. J Fr Ophtalmol 14(5): 321-326
54. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R (1998) Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res 17(1): 33-58
55. Lee VHL (1983) Esterase activities in adult rabbit eyes. J Pharm Sci 72(3): 239-244
56. Lee VH, Robinson JR (1986) Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol 2(1): 67-108
57. Liu J, Lai C, Tseng Y, Guo LSS, Hong K (2007) Liposome composition for delivery of a therapeutic agent to eyes. United States Patent 2007/0275048 A1
58. Loftsson T, Järvinen T (1999) Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 36(1): 59-79
59. Loftsson T, Stefansson E (1997) Effect of cyclodextrins on topical drug delivery to the eye. Drug Dev Ind Pharm 23(5): 473-481
60. Loftsson T, Stefansson E (2002) Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 80(2): 144-150
61. Loftsson T, Stefansson E (2007) Cyclodextrin nanotechnology for ophthalmic drug delivery. World Patent 2007/012974
62. Ludwig A (2005) The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 57(11): 1595-1639
63. Ludwig A, Van Ooteghem M (1987) The influence of the osmolality on the precorneal retention of ophthalmic solutions. J Pharm Belg 42(4): 259-266
64. Lyons RT (2004) Disinfecting and solubilizing steroid compositions. Patent 1385528
65. Mainardes RM, Silva LP (2004) Drug delivery systems: past, present, and future. Curr Drug Targets 5(5): 449-455
66. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE (2005) Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 12(21): 1544-1550
67. Marchal-Heussler L, Maincent P, Hoffman M, Spittler J, Couvreur P (1990) Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations. Int J Pharm 58: 115-122
68. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P (1991) Nanocapsules de P-bloquants, unnouveau vecteur de mkdicaments en ophthalmologie. J Fr Ophtalmol 14: 371-375
69. Marchal-Heussler L, Fessi H, Devissaguet JP, Hoffman M, Maincent P (1992) Colloidal drug delivery systems for the eye: a comparison of the efficacy of three different polymers: PolYisobutylcyanoacrylate, polylactic-co-glycolic acid, polyepsilon-caprolacton. STP Pharma Sci 2: 98-104
70. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P (1993) Poly(e-Caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res 10(3): 386-390
71. Maurice DM, Srinivas SP (1992) Use of fluorometry in assessing the efficacy of a cation-sensitive gel as an ophthalmic vehicle: comparison with scintigraphy. J Pharm Sci 81(7): 615-619
72. Mikkelson TJ, Chrai SS, Robinson JR (1973) Altered bioavailability of drugs in the eye due to drug-protein interaction. J Pharm Sci 62(10): 1648-1653
73. Miller SC, Donovan MD (1982) Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharm 12: 147-152
74. Muchtar S, Almog S, Torracca MT, Saettone MF, Benita S (1992) A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. Ophthalmic Res 24(3): 142-149
75. Muchtar S, Abdulrazik M, Frucht-Pery J, Benita S (1997) Ex-vivo permeation study of indomethacin from a submicron emulsion through albino rabbit cornea. J Control Release 44(1): 55-64
76. Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50(1): 161-177
77. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK (2009) Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release 136(1): 2-13
78. Nanjawade BK, Manvi FV, Manjappa AS (2007) In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 122(2): 119-134
79. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF (1998) Human sclera: thickness and surface area. Am J Ophthalmol 125(2): 237-241
80. Padilla De Jesus OL, Ihre HR, Gagne L, Frechet JM, Szoka FC (2002) Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem 13(3): 453-461
81. Panmai S, Alani LL (2006) Ophthalmic nanoparticulate formulation of a cyclooxygenase-2-selective inhibitor. World Patent 2006/062875
82. Prausnitz MR, Noonan JS (1998) Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 87(12): 1479-1488
83. Prow TW (2010) Toxicity of nanomaterials to the eye. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2(4): 317-333
84. Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I et al (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19(9): 1310-1316
85. Raju HB, Goldberg JL (2008) Nanotechnology for ocular therapeutics and tissue repair. Expert Rev Ophthalmol 3(4): 431-436
86. Ravi N, Ali AH (2005) Hydrogel nanocompsites for ophthalmic applications. World Patent 2005/023331
87. Robinson JR, Mlynek GM (1995) Bioadhesive and phase-change polymers for ocular drug delivery. Adv Drug Deliv Rev 16(1): 45-50
88. Rupenthal ID, Alany RG (2008) Ocular drug delivery. In: Gad SC (ed) Pharmaceutical manufacturing handbook: production and processes. John Wiley & Sons, Inc, New York
89. Sahoo SK, Labhasetwar V (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today 8(24): 1112-1120
90. Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discov Today 13(3-4): 144-151
91. Sasaki H, Yamamura K, Nishida K, Nakamura J, Ichikawa M (1996) Delivery of drugs to the eye by topical application. Prog Retin Eye Res 15(2): 583-620
92. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M et al (1999) Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst 16(1): 85-146
93. Sawhney AS, Ransone WHII (2010) Hydrogel polymeric compositions and methods. World Patent 2009/008946
94. Sharma A, Sharma US (1997) Liposomes in drug delivery: progress and limitations. Int J Pharm 154(2): 123-140
95. Simonnet J-T (2006) Cosmetic nanoemulsion comprising hydroxylated urea compound. Patent 1690522
96. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70(1-2): 1-20
97. Sultana Y, Jain R, Aqil M, Ali A (2006) Review of ocular drug delivery. Curr Drug Deliv 3(2): 207-217
98. Sun BK, Cha KH, No JW (2011) Ophthalmic nanoemulsion composition containing cyclosporine for treating ophthalmoxerosis. Patent 101008189
99. Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG (2011) Drug delivery to the posterior segment of the eye. Drug Discov Today 16(5-6): 270-277
100. Urtti A (2006) Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58(11): 1131-1135
101. Usayapant A, Karara AH, Narurkar MM (1991) Effect of 2-hydroxypropyl-beta-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. Pharm Res 8(12): 1495-1499
102. Van Ooteghem MMM (1993) Formulation of ophthalmic solutions and suspensions. Problems and Advantages. In: Edman P (ed) Biopharmaceutics of ocular drug delivery. CRC Press, Boca Raton
103. Vandamme T (2003) Use of dendrimers in an ophthalmic composition. World Patent 2003/030913
104. Vandervoort J, Ludwig A (2007) Ocular drug delivery: nanomedicine applications. Nanomedicine 2(1): 11-21
105. Vasir JK, Reddy MK, Labhasetwar V (2005) Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 1: 47-64
106. Watson PG, Young RD (2004) Scleral structure, organisation and disease. A review. Exp Eye Res 78(3): 609-623
107. Wei G, Lu W, Li C, Xie C (2010) Biological adhesive liposome preparation for eyes and preparation method thereof. Patent 101669909 A
108. Wiesel TN, Raviola E (1977) Myopia and eye enlargement after neonatal lid fusion in monkeys. Nature 266(5597): 66-68
109. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56(9): 1257-1272
110. Zarbin MA, Montemagno C, Leary JF, Ritch R (2010) Nanotechnology in ophthalmology. Can J Ophthalmol 45(5): 457-476
111. Zimmer A, Kreuter J (1995) Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 16(1): 61-73